Dr. Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks. He will review the benefits/limitations of genetic testing and pre-symptomatic screening, including his personal experience directing Stanford’s Hereditary Neuroendocrine Neoplasia Clinic. Finally, he will discuss opportunities for advancing hPPGL care and ongoing research.
Presenter:
Justin Annes, MD, PhD
Associate Professor, Stanford Department of Medicine
Dr. Annes is an Associate Professor in Stanford’s Department of Medicine and a Faculty Fellow in Stanford’s Chemistry, Engineering & Medicine for Human Health Institute (ChEM-H). He obtained his BS from Haverford College (1996), MD PHD from New York University (1996) and trained in Internal Medicine, Clinical Genetics and Chemical Biology at Brigham and Women’s Hospital / Harvard University (2011). Dr. Annes is director and founder of Stanford’s Hereditary Neuroendocrine Tumor Clinic (2012) which focuses on the longitudinal care of patients and families with inherited endocrine tumor syndromes, primarily hPPGL, MEN1 and MEN2. He participates in several neuroendocrine-focused patient advocacy / research foundations including The Pheo Para Alliance, Neuroendocrine Tumor Research Foundation and the NIH Pediatric Wildtype GIST Clinic. His NIH-funded research program is positioned at the interface of endocrine pathophysiology, synthetic chemistry and hereditary disease. The organizing principle of his research program is to harness the power of chemistry, human tissue samples and animal disease models to deliver fundamental biologic insights and develop novel therapeutic leads for the treatment of endocrine disorders.
